Published on January 12, 2009
Slide 1: Objective: To evaluate the effects of aripiprazole on tics, behavior, cognition and mood in late childhood to young adulthood Tourette syndrome (TS). Method: 10 TS patients, 9 male, mean age 17-years (range 11-32) were placed on aripiprazole 2.5 mg/d eventually up to 15 mg/d (mean 9.25 mg/d) with IRB approved informed consent. Initially concomitant medications were continued (7 on SSRI, 3 on other atypical neuroleptics and 3 on psychostimulants). Patients were monitored for 8-weeks at baseline, week 4 and 8 personally, weekly by telephone. Test comparisons baseline/week 8: Behavior-DSM-IV Rating Scale (DSM-IV), Achenbach Child Behavior Checklist (CBCL); Tics-Yale Tic Rating Scale (TRS); Cognition-Test of Variables of Attention (TOVA), 3-Letter Cancellation Test (LCT), Digit Span (DS); Mood-Children’s Depression Index (CDI), CBCL, Hamilton Depression Scale (Ham D). Results: Improved/Total: Behavior-DSM-IV 6/10 attention, 4/10 hyperactivity, 6/10 impulsivity, CBCL 6/8 attention; Tics-7/10 simple motor, 6/10 complex motor, 5/10 simple phonic, 4/10 complex phonic. Improved/Abnormal: Mood-CDI 3/5, CBCL obsessive 4/5, Ham D 0/1; Cognition-LCT 2/3, DS 3/3, TOVA 2/2. Adverse Effects: Hematology/Chemistry 0/10, 2 transient nausea, 3 > 5 percentile weight increase, 1 > 5 percentile weight decrease. Conclusion: Aripiprazole is a safe effective treatment for TS tics, behavior and cognition. Poster Presentation, 158th Annual Meeting of the American Psychiatric Association, May 21-26, 2005, Atlanta, GA. Duane DD, Heimburger GE. Open-label trial of aripiprazole in Tourette syndrome children/young adults. “2005 New Research Program and Abstracts,” in press. Open-Label Trial of Aripiprazole In Tourette Syndrome Children/Young Adults Drake D. Duane and Glenn E. Heimburger Institute for Developmental Behavioral Neurology / Arizona State UniversityScottsdale / Tempe, Arizona, U.S.A.